NASDAQ:EVAX - Evaxion Biotech A/S Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.67
  • Forecasted Upside: 325.24 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.86
▼ -0.21 (-4.14%)

This chart shows the closing price for EVAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evaxion Biotech A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVAX

Analyst Price Target is $20.67
▲ +325.24% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Evaxion Biotech A/S in the last 3 months. The average price target is $20.67, with a high forecast of $23.00 and a low forecast of $18.00. The average price target represents a 325.24% upside from the last price of $4.86.

This chart shows the closing price for EVAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Evaxion Biotech A/S.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/30/2021Lake Street CapitalInitiated CoverageBuy$21.00Medium
6/23/2021LADENBURG THALM/SH SHReiterated RatingBuyC$23.00High
3/2/2021OppenheimerInitiated CoverageOutperform$18.00High
3/2/2021LADENBURG THALM/SH SHInitiated CoverageBuyHigh
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Evaxion Biotech A/S logo
Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.
Read More

Today's Range

Now: $4.86
Low: $4.76
High: $5.02

50 Day Range

MA: $7.72
Low: $4.86
High: $12.68

52 Week Range

Now: $4.86
Low: $4.75
High: $25.04

Volume

278,653 shs

Average Volume

337,990 shs

Market Capitalization

$109.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Evaxion Biotech A/S?

The following sell-side analysts have issued stock ratings on Evaxion Biotech A/S in the last twelve months: LADENBURG THALM/SH SH, Lake Street Capital, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for EVAX.

What is the current price target for Evaxion Biotech A/S?

3 Wall Street analysts have set twelve-month price targets for Evaxion Biotech A/S in the last year. Their average twelve-month price target is $20.67, suggesting a possible upside of 325.2%. LADENBURG THALM/SH SH has the highest price target set, predicting EVAX will reach $23.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $18.00 for Evaxion Biotech A/S in the next year.
View the latest price targets for EVAX.

What is the current consensus analyst rating for Evaxion Biotech A/S?

Evaxion Biotech A/S currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EVAX will outperform the market and that investors should add to their positions of Evaxion Biotech A/S.
View the latest ratings for EVAX.

What other companies compete with Evaxion Biotech A/S?

How do I contact Evaxion Biotech A/S's investor relations team?

Evaxion Biotech A/S's physical mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The company's listed phone number is 45-5353-1850 and its investor relations email address is [email protected] The official website for Evaxion Biotech A/S is www.evaxion-biotech.com.